, Volume 42, Issue 2, pp 506–515 | Cite as

Compound GDC, an Isocoumarin Glycoside, Protects against LPS-Induced Inflammation and Potential Mechanisms In Vitro

  • Yuqin Zhang
  • Guohong Yan
  • Chengtao Sun
  • Lihong Nan
  • Xiaoying Wang
  • Wei XuEmail author
  • Kedan ChuEmail author


Compound 3R-(4′-hydroxyl-3′-O-β-D-glucopyranosyl phenyl)-dihydro isocoumarin (GDC) is a natural isocoumarin, recently isolated from the stems of H. paniculiflorum. However, we know little about the effects of GDC on rheumatoid arthritis (RA). This study aims to investigate the protective effects and potential mechanisms of GDC against LPS-induced inflammation in vitro. Fibroblast-like synoviocytes (FLSs) obtained from synovial tissue of rats were induced by lipopolysaccharide (LPS) and treated with GDC. Cell viability was determined by mitochondrial-respiration-dependent3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. Secretion of various inflammatory mediators was analyzed by ELISA and RayBio® Rat Cytokine Antibody Array. Potential mechanisms that are associated with anti-inflammatory effect were examined by Western blot. Results showed that GDC significantly inhibited the production of tumor necrosis factor alpha (TNF-α) and interleukin- (IL-) 6 induced by LPS. GDC also reduced the expression of inducible nitric oxide synthase (iNOS), TNF-α, IL-6, and IL-1β, as well as proinflammatory cytokines such as activin A, ciliary neurotrophic factor (CNTF), fractalkine, IFN-γ, IL-4, and TIMP-1. Moreover, GDC inhibited LPS-induced phosphorylation of extracellular regulated protein kinases (ERK1/2), p38 mitogen-activated protein kinases (p38), c-Jun N-terminal kinase (JNK), and IκB. And GDC also blocked NF-κBp65 nuclear translocation. All the results suggested that the protective effects of GDC against LPS-induced inflammation in vitro may be related with NF-κB and JNK signaling pathway.


rheumatoid arthritis isocoumarin fibroblast-like synoviocyte inflammation NF-κB signaling pathway MAPK signaling pathway 


Funding Information

The project was financially supported by Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of Education of Hainan Normal University, the National Natural Science Foundation of China (NO.81370096), and Fujian Provincial Department of Education to Support Provincial University Special Project (No. JK2017023).

Compliance with Ethical Standards

Conflict of Interests

The authors declare that they have no conflicts of interest.


  1. 1.
    Nakken, B., G. Papp, V. Bosnes, M. Zeher, G. Nagy, and P. Szodoray. 2017. Biomarkers for rheumatoid arthritis: From molecular processes to diagnostic applications-current concepts and future perspectives. Immunology Letters 189: 13–18.CrossRefGoogle Scholar
  2. 2.
    Neumann, E., S. Lefevre, B. Zimmermann, S. Gay, and U. Muller-Ladner. 2010. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol 16: 458–468.CrossRefGoogle Scholar
  3. 3.
    Noss, E.H., and M.B. Brenner. 2008. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 223: 252–270.CrossRefGoogle Scholar
  4. 4.
    Bartok, B., and G.S. Firestein. 2010. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol 233: 233–255.CrossRefGoogle Scholar
  5. 5.
    Brennan, F.M., and I.B. McInnes. 2008. Evidence that cytokines play a role in rheumatoid arthritis. The Journal of Clinical Investigation 118: 3537–3545.CrossRefGoogle Scholar
  6. 6.
    Alam, J., I. Jantan, and S.N.A. Bukhari. 2017. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Biomedicine & Pharmacotherapy 92: 615–633.CrossRefGoogle Scholar
  7. 7.
    Herman, S., G. Kronke, and G. Schett. 2008. Molecular mechanisms of inflammatory bone damage: Emerging targets for therapy. Trends in Molecular Medicine 14: 245–253.CrossRefGoogle Scholar
  8. 8.
    Baschant, U., N.E. Lane, and J. Tuckermann. 2012. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nature Reviews Rheumatology 8: 645–655.CrossRefGoogle Scholar
  9. 9.
    Albrecht, K., and U. Muller-Ladner. 2010. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clinical and Experimental Rheumatology 28: S95–S101.Google Scholar
  10. 10.
    Wu, S.Y., Y.H. Fu, Q. Zhou, M. Bai, G.Y. Chen, S.Y. Zhao, C.R. Han, and X.P. Song. 2018. Bioactive phenolic and Isocoumarin glycosides from the stems of Homalium paniculiflorum. Molecules 23: 472.CrossRefGoogle Scholar
  11. 11.
    Ekabo, O.A., N.R. Farnsworth, T. Santisuk, and V. Reutrakul. 1993. A phytochemical investigation of Homalium ceylanicum. Journal of Natural Products 56: 699–707.CrossRefGoogle Scholar
  12. 12.
    Ekabo, O.A., N.R. Farnsworth, T. Santisuk, and V. Reutrakul. 1993. Phenolic, iridoid and ionyl glycosides from Homalium ceylanicum. Phytochemistry 32: 747–754.CrossRefGoogle Scholar
  13. 13.
    Shaari, K., and P.G. Waterman. 1995. Glucosides of 2,5-dihydroxybenzyl alcohol from Homalium longifolium. Phytochemistry 39: 1415–1421.CrossRefGoogle Scholar
  14. 14.
    Okokon, J.E., P.J. Okokon, A. Dar Farooq, and M.I. Choudhary. 2013. Anti-inflammatory and antinociceptive activities of Homalium letestui. Pharmaceutical Biology 51: 1459–1466.CrossRefGoogle Scholar
  15. 15.
    Shaari, K., and P.G. Waterman. 1996. D: A-friedo-oleanane triterpenes from the stem of Homalium longifolium. Phytochemistry 41: 867–869.CrossRefGoogle Scholar
  16. 16.
    Charubala, R., A. Guggisberg, M. Hesse, and H. Schmid. 1974. Natural occurrence of 3-phenyl-isocoumarin. Helvetica Chimica Acta 57: 1096–1097.CrossRefGoogle Scholar
  17. 17.
    Govindachari, T.R., P.C. Parthasarathy, H.K. Desai, and K.S. Ramachandran. 1975. Homalicine and (−)-dihydrohomalicine, two new isocoumarin glucosides from Homalium zeylanicum. Indian Journal of Chemistry 13: 537–540.Google Scholar
  18. 18.
    Pais, M., R. Sarfati, F.X. Jarreau, and R. Goutarel. 1973. Homalium alkaloids: Structure of homaline, hopromine, hoprominol and hopromalinol. Tetrahedron 29: 1001–1010.CrossRefGoogle Scholar
  19. 19.
    Wu, S.Y., Y.H. Fu, G.Y. Chen, X.B. Li, Q. Zhou, C.R. Han, X.J. Du, M.L. Xie, and G.G. Yao. 2015. Cytotoxic xanthenes derivatives from Homalium paniculiflorum. Phytochemistry Letters 11: 236–239.CrossRefGoogle Scholar
  20. 20.
    Song, X.P., C.R. Han, J. Yu, Q.W. Yin, J.F. Xu, H.W. Song, and X.M. Song. 2013. Chemical constituents from the stems of Homalium paniculiflorum. Chin J Exp Tradit Med 19: 85–88.Google Scholar
  21. 21.
    McInnes, I.B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews. Nat Rev Immunol 7: 429–442.CrossRefGoogle Scholar
  22. 22.
    Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. The New England Journal of Medicine 344: 907–916.CrossRefGoogle Scholar
  23. 23.
    Davis, J.M., III, and E.L. Matteson. 2009. Cytokine biomarkers and the promise of personalized therapy in rheumatoid arthritis. Reumatología Clínica 5: 143–146.CrossRefGoogle Scholar
  24. 24.
    Jazayeri, J.A., G.J. Carroll, and A.B. Vernallis. 2010. Interleukin-6 subfamily cytokines and rheumatoid arthritis: Role of antagonists. International Immunopharmacology 10: 1–8.CrossRefGoogle Scholar
  25. 25.
    Yoon, H.Y., E.G. Lee, H. Lee, I.J. Cho, et al. 2013. Kaempferol inhibits IL-1β-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX-2, PGE2 and MMPs. International Journal of Molecular Medicine 32: 971–977.CrossRefGoogle Scholar
  26. 26.
    Nishina, N., Y. Kaneko, H. Kameda, M. Kuwana, and T. Takeuchi. 2013. Reduction of plasma IL-6 but not TNF-alpha by methotrexate in patients with early rheumatoid arthritis: A potential biomarker for radiographic progression. Clinical Rheumatology 32: 1661–1666.CrossRefGoogle Scholar
  27. 27.
    Li, X., C. Jiang, and W. Zhu. 2017. Crocin reduces the inflammation response in rheumatoid arthritis. Bioscience, Biotechnology, and Biochemistry 81: 891–898.CrossRefGoogle Scholar
  28. 28.
    Hoesel, B., and J.A. Schmid. 2013. The complexity of NF-κB signaling in inflammation and cancer. Molecular Cancer 12: 86.CrossRefGoogle Scholar
  29. 29.
    Bak, M.-J., S.-G. Hong, J.-W. Lee, and W.-S. Jeong. 2012. Red ginseng marc oil inhibits iNOS and COX-2 via NFκB and p38 pathways in LPS-stimulated RAW 2 264.7 macrophages. Molecules 17: 13769–13786.CrossRefGoogle Scholar
  30. 30.
    Lee, Y., J.K. Yun, M.H. Kim, et al. 2016. MAPK cascades in guard cell signal transduction. Frontiers in Plant Science 7: 80.Google Scholar
  31. 31.
    Baeza-Raja, B., and P. Muñoz-Cánoves. 2004. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: Role of interleukin-6. Molecular Biology of the Cell 15: 2013–2026.CrossRefGoogle Scholar
  32. 32.
    Finco, T., and A. Baldwin. 1995. Mechanistic aspects of NF-κB regulation: The emerging role of phosphorylation and proteolysis. Immunity 3: 263–272.CrossRefGoogle Scholar
  33. 33.
    Silva, E., and P. Soares-da-Silva. 2012. New insights into the regulation of Na+, K+-ATPase by ouabain. International Review of Cell and Molecular Biology 294: 99–132.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmacy College of Fujian University of Traditional Chinese MedicineFuzhouPeople’s Republic of China
  2. 2.Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of EducationHainan Normal UniversityHaikouPeople’s Republic of China
  3. 3.State Key Laboratory of Chinese Pharmacies of Fujian Provincial Department of Science and Technology of Fujian University of Traditional Chinese MedicineFuzhouPeople’s Republic of China
  4. 4.People’s Hospital Affiliated to Fujian University of Traditional Chinese MedicineFuzhouPeople’s Republic of China

Personalised recommendations